Aharon Azagury

Prof. Dr. Aharon Azagury

Ariel University, Ariel, Israel
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Aharon AzaguryAharon Azagury
Aharon Azagury
LKLuai Khoury
Luai Khoury
GEGiora Enden
Giora Enden
Joseph KostJoseph Kost
Joseph Kost

14 July 2024 in Small
Verified
Journal Article
Open access
DPDhaval T Patel
Dhaval T Patel
JSJyoti Solanki
Jyoti Solanki
MKMafatlal M. Kher
Mafatlal M. Kher
Aharon AzaguryAharon Azagury
Aharon Azagury
This review explores the evolution of lipid‐based nanoparticles (LBNPs) for drug delivery (DD). Herein, LBNPs are classified into liposomes and cell membrane‐based nanoparticles (CMNPs), each with unique advantages and challenges. Conventional LBNPs possess drawbacks such as poor targeting, quick clearance, and limited biocompatibility. One of the possible alternatives to overcome these challenges is surface modification of nanoparticles (NPs) with materials such as polyethylene glycol (PEG), aptamers, antibody fragments, peptides, CD44, hyaluronic acid, folic acid, palmitic acid, and lactoferrin. Thus, the main focus of this review will be on the different surface modifications that enable LBNPs to have beneficial properties for DD, such as enhancing mass transport properties, immune evasion, improved stability, and targeting. Moreover, various CMNPs are explored used for DD derived from cells such as red blood cells (RBCs), platelets, leukocytes, cancer cells, and stem cells, highlighting their unique natural properties (e.g., biocompatibility and ability to evade the immune system). This discussion extends to the biomimicking of hybrid NPs accomplished through the surface coating of synthetic (mainly polymeric) NPs with different cell membranes. This review aims to provide a comprehensive resource for researchers on recent advances in the field of surface modification of LBNPs and CMNPs. Overall, this review provides valuable insights into the dynamic field of lipid‐based DD systems.

1 July 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
EAEliz Amar-Lewis
Eliz Amar-Lewis
Aharon AzaguryAharon Azagury
Aharon Azagury
RCRamesh Chintakunta
Ramesh Chintakunta
RGRiki Goldbart
Riki Goldbart
TTTamar Traitel
Tamar Traitel
Joseph KostJoseph Kost
Joseph Kost

14 July 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
VRValeria Rahamim
Valeria Rahamim
Aharon AzaguryAharon Azagury
Aharon Azagury

21 February 2024 in Marine Drugs
Verified
Journal Article
Open access
PDF file
EDEliyahu Drori
Eliyahu Drori
DPDhaval T Patel
Dhaval T Patel
SCSarah Coopersmith
Sarah Coopersmith
VRValeria Rahamim
Valeria Rahamim
CDChen Damti
Chen Damti
Aharon AzaguryAharon Azagury
Aharon Azagury
Drug administration by oral delivery is the preferred route, regardless of some remaining challenges, such as short resident time and toxicity issues. One strategy to overcome these barriers is utilizing mucoadhesive vectors that can increase intestinal resident time and systemic uptake. In this study, biomimetic nanoparticles (NPs) were produced from 14 types of edible algae and evaluated for usage as oral DDSs by measuring their size, surface charge, morphology, encapsulation efficiency, mucoadhesion force, and cellular uptake into Caco-2 cells. The NPs composed of algal materials (aNPs) exhibited a spherical morphology with a size range of 126–606 nm and a surface charge of −9 to −38 mV. The mucoadhesive forces tested ex vivo against mice, pigs, and sheep intestines revealed significant variation between algae and animal models. Notably, Arthospira platensis (i.e., Spirulina) NPs (126 ± 2 nm, −38 ± 3 mV) consistently exhibited the highest mucoadhesive forces (up to 3127 ± 272 µN/mm²). Moreover, a correlation was found between high mucoadhesive force and high cellular uptake into Caco-2 cells, further supporting the potential of aNPs by indicating their ability to facilitate drug absorption into the human intestinal epithelium. The results presented herein serve as a proof of concept for the possibility of aNPs as oral drug delivery vehicles.

1 June 2021 in Polymer
Verified
Journal Article
Closed access
CBCameron Baptista
Cameron Baptista
Aharon AzaguryAharon Azagury
Aharon Azagury
CBChristopher M. Baker
Christopher M. Baker
EMEdith Mathiowitz
Edith Mathiowitz